Takeda Pharmaceutical Company Limited TAK
As ofNov 20, 2026, 3:19 PM EST
- YTD
- +40.44%
- 1 year
- +55.73%
5D +0.07 (+0.32%)
- Market cap
- 69.95B
- Revenue (ttm)
- 4.69T
- Profit margin
- 0.87%
- EPS (ttm)
- 0.07
- Shares out
- 3.19B
- P/E ratio
- 312.79
- Forward P/E
- 40.42
- Dividend
- 0.62 (2.22%)
- Ex-dividend date
- Mar 31, 2026
- YTD return
- +40.44%
- 1-year return
- +55.73%
- Volume
- 2.58M
- Avg volume
- 2.70M
- Open
- 21.82
- Previous close
- 21.41
- Day's range
- 21.81 – 22.07
- 52-week range
- 14.09 – 22.07
- Beta
- 0.08
- Analysts
- Strong Buy
- Price target
- 24.51 (+11.9%)
- Earnings date
- Jan 28, 2027
- 50-day average
- 19.59
Key statistics
- 200-day average
- 17.84
- Enterprise value
- 5.01T
- PEG ratio
- 0.48
- Price / sales
- 0.01
- Price / book
- 1.46
- Payout ratio
- 426.53%
- Revenue growth
- 6.70%
- Free cash flow
- 681.38B
- Total cash
- 418.53B
- Total debt
- 5.36T
- Return on equity
- 0.56%
- Short % of float
- 0.10%
Fundamental scorecard
12 of 25 checks passed on TAK’s reported financials
12of 25 checks passed
- Value 1 of 5
- Growth 4 of 5
- Profitability 2 of 5
- Financial health 1 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 20.76
- Target (mean)
- 24.51
- Target (high)
- 26.74
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 0.1417 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.31 | 0.3852 | +0.08 | +24.26% |
| Jul 30, 2026 | Jun 30, 2026 | 0.1689 | 0.225 | +0.06 | +33.21% |
| May 13, 2026 | Mar 31, 2026 | 0.21 | -0.04919 | -0.26 | -123.42% |
| Jan 29, 2026 | Dec 31, 2025 | 0.55 | 0.2131 | -0.34 | -61.25% |
| Oct 30, 2025 | Sep 30, 2025 | 0.44 | -0.02493 | -0.46 | -105.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | TD Cowen | main | Outperform | Outperform |
| Apr 4, 2023 | TD Cowen | main | — | Outperform |
| Mar 16, 2023 | B of A Securities | up | Neutral | Buy |
| Jul 19, 2022 | Cowen & Co. | up | Market Perform | Outperform |
| Oct 7, 2021 | Morgan Stanley | down | Overweight | Equal-Weight |
| Mar 11, 2020 | JP Morgan | main | — | Overweight |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Japan
- Website
- takeda.com
News
Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Takeda Pharmaceutical Co Q2 2026 Earnings Call Transcript Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate
Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements
Your note
Sign in to keep a note on TAK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BITETTI TERESA MARIE | Officer | Sale | Aug 9, 2026 | 252,010 |
| DUPREY LAUREN RUSCKOWSKI | Officer | Sale | Sep 13, 2026 | 191,522 |
| FURNEY NATALIE ANNE MARIE | Officer | Sale | Aug 9, 2026 | 204,298 |
| KIM JULIE SO-YOUNG | Chief Executive Officer | Sale | Aug 9, 2026 | 391,489 |
| PACHECO RHONDA JANICE | Officer | Sale | Aug 9, 2026 | 182,507 |
| PIGNAGNOLI AGOSTI MARCELLO | Officer | Sale | Aug 9, 2026 | 176,977 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Capital Research Global Investors | 0.84% | 26,952,673 | 577.33M | Sep 29, 2026 |
| FMR, LLC | 0.34% | 10,974,215 | 235.07M | Sep 29, 2026 |
| Morgan Stanley | 0.26% | 8,234,395 | 176.38M | Sep 29, 2026 |
| Adage Capital Partners GP L.L.C. | 0.22% | 7,200,771 | 154.24M | Sep 29, 2026 |
| Goldman Sachs Group Inc | 0.17% | 5,541,243 | 118.69M | Sep 29, 2026 |
| Brandes Investment Partners L.P. | 0.13% | 4,238,825 | 90.80M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AMERICAN MUTUAL FUND | 0.57% | 18,157,900 | 388.94M | Sep 29, 2026 |
| Capital Income Builder | 0.23% | 7,343,700 | 157.30M | Sep 29, 2026 |
| VanEck ETF Trust-VanEck Pharmaceutical ETF | 0.05% | 1,522,522 | 32.61M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT Value Line Dividend Index Fd. | 0.05% | 1,714,201 | 36.72M | Sep 29, 2026 |
| GOLDMAN SACHS TRUST-Goldman Sachs Income Builder Fund | 0.02% | 494,442 | 10.59M | Jul 30, 2026 |
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.02% | 711,871 | 15.25M | Jul 30, 2026 |
